Q1 2023 EARNINGS CALL

PRESENTATION.

SEVENUM, 2 MAY 2023

2

Q1 2023

EARNINGS

CALL

LIVE FROM

OUR HEADQUARTERS

IN SEVENUM.

JASPER EENHORST, CFO.

STEFAN FELTENS, CEO.

3

TODAY'S AGENDA.

BUSINESS

PERFORMANCE.

UPDATE ON

BUSINESS AND STRATEGY.

4

BUSINESS PERFORMANCE.

HIGHLIGHTS Q1 2023:

5

STRONG Q1 WITH 22% SALES GROWTH AND EBITDA MARGIN UP 3.8PP VS. LAST YEAR TO +2.4%.

  • DOUBLE-DIGITSALES GROWTH - IN ALL SEVEN COUNTRIES.

NON-RX SALES GROWTH 23%, TOTAL SALES GROWTH 22%.

ACTIVE CUSTOMER BASE UP 0.4M TO 9.7M.

CONTINUED HIGH CUSTOMER SATISFACTION; NPS ABOVE 70.

  • EFFICIENCY GAINS AND SCALE EFFECTS DRIVE MARGIN.

Q1 ADJ. EBITDA MARGIN 2.4%, 3.8 PP BETTER THAN LAST YEAR'S Q1.

  • OPERATING CASH FLOW EUR +44M.

EBITDA EUR 9M AND FAVOURABLE SEASONAL WORKING CAPITAL MOVEMENTS.

  • SUSTAINABILITY: MSCI ESG RATING UPGRADE TO TRIPLE-A.

NOW SHOP APOTHEKE EUROPE IS AMONG LEADING TOP 4% GLOBALLY IN BENCHMARK.

  • STRATEGIC PARTNERSHIP WITH GALENICA, CREATING THE LEADING ONLINE

PHARMACY IN SWITZERLAND.

CLOSING EXPECTED THIS H1; MEDISERVICE NUMBERS FOR FULL YEAR 2023: SALES OF AROUND CHF 450 MILLION AND EBITDA MARGIN 2 TO 3%. CONSOLIDATED AS OF CLOSING.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Shop Apotheke Europe NV published this content on 02 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 May 2023 04:45:09 UTC.